688566 Jiangsu Jibeier Pharmaceutical Co., Ltd.
- 26.67
- +0.15+0.57%
Jiangsu Jibeier Pharmaceutical Co., Ltd. News
Gibbel (688566.SH) released 2023 annual results, with net profit of 219 million yuan, an increase of 41.65% over the previous year
Gibbel (688566.SH) released its 2023 annual report. The company achieved operating income of 8.6 during the reporting period...
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) 11% Gain Last Week Benefited Both Private Companies Who Own 37% as Well as Insiders
Key Insights Jiangsu Jibeier Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 2 investors hav
Could The Market Be Wrong About Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE:688566) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Jiangsu Jibeier Pharmaceutical's (SHSE:688566) recent performance, when its stock has declined 11% over the past three months. However, stock prices are us
We Ran A Stock Scan For Earnings Growth And Jiangsu Jibeier Pharmaceutical (SHSE:688566) Passed With Ease
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But as Peter Lynch said in One Up On Wall
The net profit of Gibbel (688566.SH) in 2023 was 216 million yuan, up 39.57% year-on-year
Gibbel (688566.SH) disclosed the 2023 annual results report. During the reporting period, the company achieved total operating revenue...
Gibbel (688566.SH): Situations where the main products are not directly sold overseas
GLONGHUI, January 16丨Gibbel (688566.SH) said on the investor interactive platform that currently, the company's main products are not directly sold overseas. For details of the company's main business sales by region, please refer to the company's annual report. The company will develop product sales strategies according to business development needs.
Gibbel (688566.SH): An efficient liquid chromatographic analysis method for determining the components of related substances in halomethasone cream obtained an invention patent
Gelonghui, January 9, 丨 Jiber (688566.SH) announced that the company recently received an invention patent certificate issued by the State Intellectual Property Office. The name of the invention patent is a high-efficiency liquid chromatographic analysis method for determining the components of relevant substances in halomethasone cream. The invention patent relates to a field of pharmaceutical analysis, specifically to a high-efficiency liquid chromatographic analysis method for determining the components of related substances in halometasone cream.
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Market Cap Dropped CN¥390m Last Week; Private Companies Bore the Brunt
Key Insights Significant control over Jiangsu Jibeier Pharmaceutical by private companies implies that the general public has more power to influence management and governance-related decisions A to
Gibbel (688566.SH): Received an invention patent certificate issued by the US Patent and Trademark Office
On December 17, Gelonghui (688566.SH) announced that the company recently received an invention patent certificate issued by the US Patent and Trademark Office. The name is a hydrophobic anti-tumor drug containing ketocarbonyl and its conjugates, nanopreparations containing conjugates, and their preparation methods and applications. The invention patent is a patent for the compound and use of the new anti-tumor drug JJH201601 by a company authorized by the US Patent and Trademark Office.
Are Robust Financials Driving The Recent Rally In Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) Stock?
Most readers would already be aware that Jiangsu Jibeier Pharmaceutical's (SHSE:688566) stock increased significantly by 13% over the past three months. Given that the market rewards strong financia
Gilbert (688566.SH) released the first three quarter results, net profit of 155 million yuan, up 95.65% year on year
Gilbert (688566.SH) released its report for the first three quarters of 2023, with revenue of 617 million yuan, compared to the same period last year...
With EPS Growth And More, Jiangsu Jibeier Pharmaceutical (SHSE:688566) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage
Gilbel (688566.SH) has obtained an invention patent in the field of pharmaceutical chemical crystal preparation technology
Gibel (688566.SH) announced that the company recently received an invention issued by the State Intellectual Property Office...
Private Companies Invested in Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE:688566) up 6.9% Last Week, Insiders Too Were Rewarded
Key Insights The considerable ownership by private companies in Jiangsu Jibeier Pharmaceutical indicates that they collectively have a greater say in management and business strategy A total of 2 in
Gilbel (688566.SH) released first-half results, net profit of 96.263,200 yuan, an increase of 128.59% over the previous year
Gilbel (688566.SH) released the 2023 semi-annual report. The company's revenue was 419 million yuan, the same as...
Declining Stock and Decent Financials: Is The Market Wrong About Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE:688566)?
Jiangsu Jibeier Pharmaceutical (SHSE:688566) has had a rough month with its share price down 27%. However, the company's fundamentals look pretty decent, and long-term financials are usually aligned
Gibbel (688566.SH): The company is advancing JH201601 phase I clinical research in an orderly manner
Gronway July 28丨Some investors asked Gibbel (688566.SH): Please tell me the progress of the company's research and development of JJH201601, a new anti-tumor drug? Gibbel replied: The company is developing a new anti-tumor drug JH201601, a new compound obtained through molecular design and efficacy testing, and a class of new anti-tumor drugs developed based on the liposomal drug research and development technology platform. Studies have shown that injectable JH201601 liposomes have remarkable tumor-suppressing effects on various solid tumor CDX models, and they are all stronger than imported docetaxel injections (trade name: Tesotide), and have lower levels
Gibbel (688566.SH): The sales scale of Ricojun films is on the rise, and the development prospects are broad
GLONGHUY July 28丨Some investors asked Gibel (688566.SH): Where is the main room for growth in Likojun films in the future? Gibbel replied: The overall market capacity of whitening drugs is huge, the potential is huge, the market prospects are broad, and they have huge market space and potential. As a mainstream product in the field of whitening chemicals, Likejun tablets have broad prospects for future development. On the one hand, sales data analysis shows that there is an imbalance in the development of Ricojun tablets in different regions, cities, and hospitals, and there is still a large gap in the market from the perspective of the national market; on the other hand, effective use in the oncology field will provide a new addition to Likejun tablets
Gibbel (688566.SH): Currently, there is only one manufacturer that has obtained approval for the production of Niquolol tablets
Gronway July 28丨Some investors asked Gibel (688566.SH): How does the company view the risk of nifenolol tablets being copied? Gibbel's reply: Using advanced compound formulation research and development technology to innovatively use the synergistic antihypertensive mechanism of CCB and beta blockers to effectively promote group prevention and treatment of hypertension, nifenolol tablets have obtained many invention patents for related technologies. The relevant patented technologies are still under protection, and the protection period is long, constituting a high technical barrier for nigunolol tablets. Currently, there is only one manufacturer that has obtained approval for the production of niprolol tablets; not on the market
Gibbel (688566.SH): It is expected that Nivolol tablets will show a rapid growth trend in the future
GLONGHUY July 28丨Some investors asked Gibbel (688566.SH): As a key product promoted by the company, what specific promotion measures are currently in place for nigunlol tablets? Gibbel's reply: The main feature of nifulol tablets is that they are used to treat mild to moderate primary hypertension, and are more suitable for patients with mild to moderate hypertension combined with a fast heart rate. They are highly in line with the current clinical treatment concept of lowering blood pressure while controlling heart rate at the same time. Their efficacy has been approved and recommended by leading domestic experts. The company adopted an expert promotion model. Through the recommendations and publicity of leading experts from all over the country, experts from all provinces and cities and hospital doctors reached a consensus to advance
Analysis
Price Target
No Data
